UMIN-CTR History

Name：　　UMIN ID：


Unique ID issued by UMIN UMIN000005613
Receipt number R000006632
Scientific Title Clinical PhII Study: Investigation for safety and efficacy of bendamustine and rituximab, B-R combination therapy for the patients of recurrent and/or refractory low-grade B cell lymphoma or mantle cell lymphoma previously treated with one or two regimen including rituximab
Date of disclosure of the study information 2011/05/20
Last modified on 2016/05/07 00:43:46

No. Disposal Last modified on Item of update
1 Insert 2011/05/17 17:27:36
2 Update 2011/05/18 07:07:20 Key exclusion criteria
Key exclusion criteria
3 Update 2011/05/18 17:13:44 Key inclusion criteria
4 Update 2011/05/20 05:38:49 Acronym
5 Update 2011/05/20 05:56:40 Organization
Organization
6 Update 2011/05/20 05:59:53 Condition
Condition
Primary outcomes
Primary outcomes
7 Update 2012/05/23 15:21:41 Institute
Institute
Post marketing survey by drug manufacture etc., specified by Japanese law.
8 Update 2012/05/23 15:25:16 Last follow-up date
9 Update 2012/05/23 15:28:55 Key secondary outcomes
Key secondary outcomes
10 Update 2012/11/21 16:36:59 Acronym
Acronym
11 Update 2012/11/21 16:40:59 Institute
Institute
12 Update 2013/05/22 16:50:51 Public title
13 Update 2013/05/22 16:54:47 Narrative objectives1
Primary outcomes
Primary outcomes
14 Update 2013/05/22 17:04:11 Last name of contact person
Last name of contact person
Institutions
15 Update 2013/05/22 17:08:20 Recruitment status
Last follow-up date
16 Update 2013/11/27 12:26:50 TEL
Email
Address
Address
TEL
Name of person sending information
17 Update 2013/11/27 12:55:58 Publication of results
URL related to results and publications
Other related information
18 Update 2013/11/27 13:02:45 Date trial data considered complete
Date analysis concluded
19 Update 2015/07/15 16:10:43 URL related to results and publications
Results
Results
Other related information
20 Update 2016/05/07 00:39:17 Recruitment status
Last follow-up date
Date trial data considered complete
Date analysis concluded
21 Update 2016/05/07 00:43:46 Name of primary person or sponsor
Organization